Literature DB >> 22049515

Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia.

Jing Chen1, Mike Petrus, Richard Bamford, Joanna H Shih, John C Morris, John E Janik, Thomas A Waldmann.   

Abstract

Large granular lymphocyte (LGL) leukemia is a clonal lymphoproliferative disease of mature T and natural killer cells. The etiology of LGL leukemia is unknown. IL-15 is an inflammatory cytokine that stimulates T and natural killer cells and is critical for their survival and proliferation. IL-15 signals through a heterotrimeric receptor that is composed of a private receptor, IL-15Rα and IL-2/IL-15Rβ and γ(c) shared with IL-2. Using a newly developed assay, we demonstrated increased levels of soluble IL-15Rα in the serum of patients with T-LGL leukemia. Furthermore, IL-15Rα mRNA levels were also up-regulated in the PBMCs of these patients. FACS analysis indicated that IL-15Rα was expressed both on monocytes as well as on some CD8+ leukemic cells of the patients. Interestingly, the mRNA levels of IFN-γ, a known inducer of IL-15Rα, were also up-regulated in patients' PBMCs. Moreover, PBMCs of some T-LGL patients proliferated at higher levels in response to exogenously added IL-15 compared with those of normal donors. In summary, our study demonstrated increased expression of IL-15Rα in T-LGL leukemia. It is conceivable that higher IL-15Rα expression may lower IL-15 response threshold in vivo and, therefore, may contribute to the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22049515      PMCID: PMC3251226          DOI: 10.1182/blood-2011-04-346759

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production.

Authors:  Z Liu; K Geboes; S Colpaert; G R D'Haens; P Rutgeerts; J L Ceuppens
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

Review 2.  Large granular lymphocyte leukemia.

Authors:  Lubomir Sokol; Thomas P Loughran
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

3.  IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS).

Authors:  P Kivisäkk; D Matusevicius; B He; M Söderström; S Fredrikson; H Link
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

4.  Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia.

Authors:  John C Morris; John E Janik; Jeffrey D White; Thomas A Fleisher; Margaret Brown; Mitsuru Tsudo; Carolyn K Goldman; Bonita Bryant; Michael Petrus; Lois Top; Cathryn C Lee; Wendy Gao; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-30       Impact factor: 11.205

5.  IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice.

Authors:  J Marks-Konczalik; S Dubois; J M Losi; H Sabzevari; N Yamada; L Feigenbaum; T A Waldmann; Y Tagaya
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

6.  Large Granular Lymphocyte Leukemia.

Authors: 
Journal:  Cancer Control       Date:  1998-01       Impact factor: 3.302

7.  Safety and immunologic effects of IL-15 administration in nonhuman primates.

Authors:  Carolina Berger; Michael Berger; Robert C Hackman; Michael Gough; Carole Elliott; Michael C Jensen; Stanley R Riddell
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

8.  The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

Authors:  R N Bamford; A J Grant; J D Burton; C Peters; G Kurys; C K Goldman; J Brennan; E Roessler; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

9.  Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells.

Authors:  Rima Koka; Patrick Burkett; Marcia Chien; Sophia Chai; David L Boone; Averil Ma
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

Review 10.  The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders.

Authors:  Ranran Zhang; Mithun Vinod Shah; Thomas P Loughran
Journal:  Hematol Oncol       Date:  2010-09       Impact factor: 5.271

View more
  26 in total

Review 1.  Cytokines in the Treatment of Cancer.

Authors:  Kevin C Conlon; Milos D Miljkovic; Thomas A Waldmann
Journal:  J Interferon Cytokine Res       Date:  2018-06-11       Impact factor: 2.607

2.  IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.

Authors:  Fella Tamzalit; Isabelle Barbieux; Ariane Plet; Julie Heim; Steven Nedellec; Sébastien Morisseau; Yannick Jacques; Erwan Mortier
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

3.  Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Authors:  Rashmi Gupta; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

Review 4.  The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development.

Authors:  T F Sumter; L Xian; T Huso; M Koo; Y-T Chang; T N Almasri; L Chia; C Inglis; D Reid; L M S Resar
Journal:  Curr Mol Med       Date:  2016       Impact factor: 2.222

5.  Inflammaging in cervical and lumbar degenerated intervertebral discs: analysis of proinflammatory cytokine and TRP channel expression.

Authors:  Aleksandra Sadowska; Ermioni Touli; Wolfgang Hitzl; Helen Greutert; Stephen J Ferguson; Karin Wuertz-Kozak; Oliver N Hausmann
Journal:  Eur Spine J       Date:  2017-12-04       Impact factor: 3.134

6.  Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Rα.

Authors:  Jing Chen; Lionel Feigenbaum; Parirokh Awasthi; Donna O Butcher; Miriam R Anver; Yelena G Golubeva; Richard Bamford; Xiaojie Zhang; Mark B St Claire; Craig J Thomas; Valentina Discepolo; Bana Jabri; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-31       Impact factor: 11.205

Review 7.  The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy.

Authors:  Thomas A Waldmann
Journal:  Cancer Immunol Res       Date:  2015-03       Impact factor: 11.151

Review 8.  Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia.

Authors:  HeeJin Cheon; Karolina H Dziewulska; Katharine B Moosic; Kristine C Olson; Alejandro A Gru; David J Feith; Thomas P Loughran
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

9.  Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia.

Authors:  Thomas A Waldmann; Kevin C Conlon; Donn M Stewart; TatYana A Worthy; John E Janik; Thomas A Fleisher; Paul S Albert; William D Figg; Shawn D Spencer; Mark Raffeld; Jean R Decker; Carolyn K Goldman; Bonita R Bryant; Michael N Petrus; Stephen P Creekmore; John C Morris
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

Review 10.  Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.

Authors:  Francis Leblanc; Dan Zhang; Xin Liu; Thomas P Loughran
Journal:  Future Oncol       Date:  2012-07       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.